Lenalidomide and dexamethasone for multiple myeloma

Research output: Contribution to journalArticlepeer-review


Patients with smouldering or asymptomatic multiple myeloma (SMM) are not treated until symptomatic disease develops. SMM is characterised by a serum monoclonal protein component of 3 g/dL or plasma cell infiltration into bone marrow of 10% or more.
Original languageEnglish
Pages (from-to)240-241
Number of pages2
JournalJournal of Pharmacy Practice and Research
Issue number3
Publication statusPublished - 2013


Dive into the research topics of 'Lenalidomide and dexamethasone for multiple myeloma'. Together they form a unique fingerprint.

Cite this